We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$154M
Cap. Flow %
18.03%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 58.93%
2 Technology 3.62%
3 Communication Services 2.25%
4 Financials 1.01%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVOK
101
DELISTED
Evoke Pharma
EVOK
$1.74M 0.2%
5,341
+1,376
+35% +$570K
NEOS
102
DELISTED
Neos Therapeutics, Inc
NEOS
$1.73M 0.2%
+170,032
New +$1.63M
CYTK icon
103
Cytokinetics
CYTK
$10.5B
$1.71M 0.2%
210,000
-17,990
-8% -$204K
PRQR icon
104
ProQR Therapeutics
PRQR
$243M
$1.71M 0.2%
530,000
– –
VTVT icon
105
vTv Therapeutics
VTVT
$127M
$1.69M 0.2%
7,042
-458
-6% -$103K
AXSM icon
106
Axsome Therapeutics
AXSM
$11.2B
$1.69M 0.2%
301,000
-200,000
-40% -$1.01M
VTGN icon
107
VistaGen Therapeutics
VTGN
$9.89M
$1.38M 0.16%
41,575
+6,295
+18% +$208K
RNTX
108
Rein Therapeutics
RNTX
$63.1M
$1.32M 0.15%
6,250
– –
RDCM icon
109
Radcom
RDCM
$171M
$1.3M 0.15%
+65,760
New +$1.34M
SNA icon
110
Snap-on
SNA
$21.2B
$1.27M 0.15%
7,292
– –
ACOR
111
DELISTED
Acorda Therapeutics
ACOR
$1.07M 0.13%
+417
New +$1.19M
RCKT icon
112
Rocket Pharmaceuticals
RCKT
$340M
$1.05M 0.12%
25,110
-75,331
-75% -$747K
FSTX
113
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$999K 0.12%
18,577
-21,277
-53% -$1.27M
ALBO
114
DELISTED
Albireo Pharma Inc
ALBO
$907K 0.11%
35,431
-73,095
-67% -$1.85M
NGNE icon
115
Neurogene
NGNE
$656M
$888K 0.1%
3,777
– –
AAP icon
116
Advance Auto Parts
AAP
$3.35B
$831K 0.1%
8,336
+5,650
+210% +$520K
RGNX icon
117
Regenxbio
RGNX
$620M
$735K 0.09%
+22,107
New +$666K
ATXS
118
DELISTED
Astria Therapeutics
ATXS
$489K 0.06%
5,467
+666
+14% +$78.4K
TJX icon
119
TJX Companies
TJX
$174B
$443K 0.05%
11,600
– –
UNH icon
120
UnitedHealth
UNH
$376B
$441K 0.05%
2,000
– –
TMX
121
DELISTED
Terminix Global Holdings, Inc.
TMX
$410K 0.05%
11,944
– –
SAGE
122
PUT
DELISTED
Sage Therapeutics
SAGE
$395K 0.05%
2,400
– –
WSO icon
123
Watsco Inc
WSO
$12.7B
$357K 0.04%
2,100
– –
MHK icon
124
Mohawk Industries
MHK
$7.5B
$303K 0.04%
1,100
– –
ECL icon
125
Ecolab
ECL
$78.1B
$268K 0.03%
2,000
– –
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $154M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.